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httcense.Abstract The objective of the study is to assess the use of ‘‘Intact’’ Breast lesion excision system as
the primary method for histopathological diagnosis of suspicious small and borderline lesions as
well as the unclassiﬁed microcalciﬁcations.
Material and method: Eighty cases were included for BLES excision of radiologically high risk
lesions.
Results: Eighty cases were successfully done, age range between 21 and 55 years old. 72.5% (58/80)
cases were done under ultrasound guidance and 27.5% (22/80) cases were done under stereotactic
guidance. Thirty percent (24/80) lesions were removed by using the 15 mm probe and 70% (56/80)
lesions were removed by using the 20 mm probe size. The main indication was complete removal of
a small indeterminate mass (30/80) followed by biopsy of unclassiﬁed micro calciﬁcations, either
without mass (18/80) or associated with a mass (16/80). Asymmetry (6/80) and distortion (4/80)hyperplasia; ADH, Atypical
a in situ; IDC, Invasive duct
ast carcinoma; LCI, lobular
449957; fax: +20 233363310.
.co (N.A. Razek).
tian Society of Radiology and
g by Elsevier
ing by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear Medicine.
p://dx.doi.org/10.1016/j.ejrnm.2013.02.012
384 N.A. Razek et al.and ﬁnally clustered micro cysts (6/80) were observed. (44/80) representing 55% were categorized as
BIRADS 3 while (36/80) about 45% were categorized as BIRADS 4.30% (24/80) of lesions were
benign (including ﬁbroadenomas, ﬁbrocystic changes and sclerosing adenosis), 52.5% (42/80) were
potentially high risk lesions (including ADH, ALH and papillomas) and 17.5% (14/80) of lesions
were malignant (including LCIS, DCIS and IDC). Open surgery was done for all the malignant
and potentially malignant lesions and there was no underestimation. However there was no enough
margin after BLES in (3/6) IDC.
Conclusion: BLES offers complete lesion removal thus much indicated in borderline lesions.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Background
High-risk benign breast lesions can create confusion for both
the patient and the clinician. High-risk breast lesions offer
varying degrees of increased risk for the future development
of breast cancer (1,2).
The term high risk lesion is given to a breast lesion that car-
ries an increased risk for the future development of breast can-
cer or carries suspicion of a more sinister pathology around or
in association with the lesion. The term has some overlap with
borderline breast disease (3). Many radiologists recommend
the excision of these lesions when they are revealed on patho-
logical analysis after a core biopsy. Lesions included in this
group are: atypical ductal hyperplasia (ADH), atypical colum-
nar cell hyperplasia, types of lobular breast neoplasia, atypical
lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS),
papillary lesions of the breast, ﬂat epithelial atypia, radial scar/
complex sclerosing lesion (1–4).
Radiologically indeterminate lesions sometimes yield an
indeterminate histopathological assessment following a radio-
logically guided biopsy. Although some centers may wish to
just follow these lesions up, increasingly these are being treated
using radiological wire localization followed by open surgery
in the form of a wide local excision (5). However many of these
are subsequently benign on ﬁnal surgical pathology. More re-
cently there has been alternative radiological management.
This has been achieved with vacuum assisted biopsy devices,
such as mammotome (Johnson and Johnson Ethicon
Endo-Surgery Inc., Cincinnati, Ohio, USA) Encor (C.R.
Bard, New York, USA) and Suros ATEC (Suros Surgical
Systems Inc., Indianapolis, USA). The advantages of these
more minimally invasive approaches will undoubtedly make
this technique increasingly popular (6). They can be performed
usually in less than 30 min, extremely tolerable to the patients,
with only local anesthesia, a minimal scar and low complica-
tion rates. These procedures are particularly suitable for young
women where risk of the lesion being non benign is very low,
and cosmoses is premium (7,8). The obvious limitation of this
technique however, is that as it is only able to remove lesions in
a ‘‘piecemeal’’ fashion. Such excisions are unable to provide an
assessment of margins of the excision, thus there is no way of
determining completeness of excision and whether any residual
lesion is left behind. While this may not be particularly rele-
vant if the lesions excised are ﬁbroadenomas, or other such
similar benign lesions, it will however obviate the vacuum as-
sisted excision from being utilized for many other more ‘‘bor-
der-line’’ lesions where completeness of excision and a full
margin status are desirable or essential (9). The breast lesionexcision system (BLES, Intact Medical, Framingham, USA),
has been recently introduced as an alternative large biopsy de-
vice to other vacuum assisted biopsy devices. It has been well
validated as a safe and efﬁcacious biopsy procedure (10). It
however has the unique feature of using radiofrequency cau-
tery to excise a small but whole sample in one piece with intact
architecture and clear margins, as a swift local anesthetic out-
patient procedure. Our unit is the ﬁrst in Egypt where the
BLES has been in operation since February 2012.
The purpose of our study is to evaluate the ability of the
BLES ‘‘Intact’’ Breast lesion excision system as the primary
method for complete excision of small indeterminate or bor-
derline lesions as well as the unclassiﬁed microcalcﬁcations in
the attempt to obviate the need for open surgery.
2. Methods
Full local hospital institutional board and medical device com-
mittee approval was obtained for this evaluationwith the BLES.
Patients with small breast lesions that were considered radiolog-
ically indeterminate (BIRADS 3& 4) were included in our study
after taking full consent and approval of the multidisciplinary
team (radiologist, surgeon, oncologist and pathologist).
The inclusion criteria include: small lesion less than 20 mm,
unclassiﬁed microcalciﬁcations, asymmetric densities, focal
distortion. Exclusion criteria: multiple lesions (not absolute;
needle for one lesion), breast augmentations, patients with im-
planted electronics such as pacemakers and lactating females.
The procedure is done under ultrasound guidance if the le-
sion is sonographically visible or under stereotactic guidance if
the lesion is only mammographically visible. Pre-procedure
adequate local anesthesia (20 ml of xylocaine–adrenaline)
was performed and a deep skin snap incision about 6 mm cut-
ting into the superﬁcial subdermal fatty stroma is needed to
facilitate the tip of the needle (probe) passage into the breast
(Fig. 1). The BLES probe consists of a suction biopsy ‘‘wand’’
connected by an extensible cutting radiofrequency ring wire
(Fig. 1). It can envelop an area of tissue ranging from 10 to
20 mm in diameter (depending on wand size) in only 8 s. The
RF is enough to excise and allow hemostasis without damag-
ing the sample. Wand sizes vary, with the smallest having a ﬁ-
nal capture diameter of 10 mm, the largest 20 mm. We utilized
15 and 20 mm wands. The BLES is activated at the touch of a
button; the metallic prongs protrude under direct vision and
encircle the target lesion (Fig. 2). The whole wand with sample
is then removed, specimen freed from the wand followed by
specimen radiograph (Fig. 1). The samples are placed in
formalin and sent to histopathology. Standard pathological
Fig. 1 (a) 6 mm skin incision, (b) BLES needle loaded with the biopsy sample surrounded by the metallic prongs, (C) tissue sample and
(d) sample radiography showing microcalciﬁcations.
Fig. 2 (a) Small 4 · 7 mm indeterminate solid hypoechoic breast mass, radiologically categorized as BIRADS 3. (b) The BLES needle
opens and the ﬁve metallic prongs (arrows) are seen surrounding the lesion to separate it from the surrounding tissue. The lesion was
totally removed and diagnosed as papilloma on histopathology.
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immunohistochemistry was routinely performed (Figs. 3–5).
Between February 2012 and September 2012, 80 patients
were included having indeterminate and borderline (BIRADS
3 & 4) breast lesions.
All cases included in this study were performed by the radi-
ologist. The radiological and pathological sizes of the removed
lesions were recorded for these lesions as well as pathological
diagnosis. Follow-up surgical excision was done for all the
malignant and some of the potentially malignant cases (38/
80) and the results of pathology were compared to the pathol-
ogy results after the BLES.3. Results
Eighty cases were successfully done, their age ranged between
21 and 55 years.
All procedures were well tolerated at the time of the proce-
dure with no or minimal discomfort. Hematoma occurred in
only three patients and vanished within 14 days after the
procedure.
72.5% (58/80) cases were done under ultrasound guidance
and 27.5% (22/80) cases were performed under stereotactic
guidance. 30% (24/80) lesions were conducted using the
Fig. 3 (a) Screening mammography of a 45 year old female with positive family history showing left UOQ asymmetric density, (b) tissue
sample removed by the BLES with minimal necrosis at the edge effect of RF and (c) histopathology of the specimen after staining with
H&E (1 · 40 microscopic magniﬁcation) showing LCIS. The breast lobules are distended by a proliferation of lobular epithelial cells
showing relatively monomorphic hyperchromatic nuclei with focal signet ring features. Re-surgery was conducted, there was no under-
estimation.
386 N.A. Razek et al.15 mm probe and 70% (56/80) lesions were conducted using
the 20 mm probe size. Mean largest radiological lesion size
was 9 mm (range 4–16 mm). All pathological specimens
yielded pathology appropriate to the target lesions, with min-
imal diathermy effects (<1 mm).
The radiological presentation is summarized in Table 1.
The commonly encountered was a small indeterminate mass
(30/80) followed by a biopsy of unclassiﬁed microcalciﬁca-
tions, either without mass (18/80) or associated with a mass
(16/80). Asymmetry (6/80) and distortion (4/80) and ﬁnally
clustered micro cysts (6/80) were observed.
As regards the BIRADS score of the study group (Table 2):
BIRADS 3 (44/80) 55% and BIRADS 4 (36/80) 45%. As re-
gards the histopathology after total excision (summarized in
Table 3), 30% (24/80) of lesions were benign (including
ﬁbroadenomas, ﬁbrocystic changes, radial scar and sclerosing
adenosis), 52.5% (42/80) were potentially high risk lesions
(including ADH, ALH and papillomas) and 17.5% (14/80)
of lesions were malignant (including LCIS, DCIS and IDC).
Re-surgery was conducted in 38 cases (14 ADH, 8 ALH, 2
LCIS, 8 DCIS and 6 IDC) after discussion with the multidisci-
plinary management team. The margin was considered ade-
quate if a 1 mm free margin around the lesion was obtained.
Free margin after BLES was obtained in 29/38 (76.3%).Malignancy was found at the margin in 1/2 LCIS, 2/8 DCIS
and 3/6 IDC. There was no underestimation of the pathology
grade in the specimens obtained by BLES as all the pathology
after open surgery was in accordance with the pathology after
BLES.4. Discussion
BLES biopsy is a well-tolerated large biopsy procedure, with
few complications. If used equivalently to a vacuum device just
to sample rather than excise a breast lesion, then both advan-
tages and disadvantages have to be considered (11,12).
Although potentially slightly faster and in providing a single
piece specimen for the pathologist, it is undoubtedly easier
and more accurate to analyze in the laboratory, many lesions
and the smaller breasts will not be suitable for this procedure
(13,14). In addition the skin incision required to introduce the
BLES is signiﬁcantly larger than most vacuum needles. There
is also the need to be extremely accurate with the needle posi-
tioning as essentially once the BLES is deployed, no further
adjustments can be made to the acquisition. Aside from a sin-
gle hematoma, there were no immediate or delayed complica-
tions and the specimens were excellent for pathological
Fig. 4 (a) Screening mammography of a 55 year old female with positive family history showing left UOQ unclassiﬁed
microcalciﬁcations, categorized as BIRADS 4b, (b) magniﬁed view of the left UOQ showing the microcalciﬁcations, (c) sample
radiography of the tissue removed by the BLES harboring the microcalciﬁcations, (d) tissue removed within the BLES needle and (e)
histopathology of the specimen after staining with H&E showing intraductal carcinoma grade two solid pattern with positive margin.
Fig. 5 (a) Sample radiography after BLES showing unclassiﬁed microcalciﬁcation radiologically categorized as BIRADS 4b within the
biopsy sample and (b) histopathology of the specimen after staining with H&E showing IDC with ﬂushed margin. Re-surgery was
conducted and no under-estimation was encountered.
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many lesions, benign lesions of suitable size and location were
effectively managed in essentially a one stop outpatient proce-
dure. The BLES has been shown to be an efﬁcacious tool in
excising small benign breast lesions with a clear margin. Inall our cases there is no residual lesion left after BLES. Our re-
sults are in accordance with the previously published (14).
A piecemeal vacuum assisted biopsy excision technique
ignores the fact that in few of these cases, e.g. papilloma some
residual lesion may be left in the breast and those are of
388 N.A. Razek et al.potential risk to have an in situ carcinoma at the edge. Without
having a complete margin of excision in these lesions that are
vacuum excised, there will be undoubtedly cases where this is
not fully removed and the residual tissue may contain the duc-
tal carcinoma in situ at the edge of the lesion. Indeed the liter-
ature as regards papilloma vacuum excision to date includes
only several small series of cases and short term follow up data
using this technique (15,16). While recurrence of a benign
ﬁbroadenoma following vacuum excision is problematic it is
not potentially life threatening, but if even low grade malig-
nancy is left behind following a vacuum excision of a papil-
loma or other borderline lesion then the consequences may
be serious. Therefore extending vacuum biopsies to indetermi-
nate and potentially malignant lesions be certainly conten-
tious, as the absence of a deﬁned margin of excision will
always be a criticism. The BLES clearly circumvents this prob-
lem and in a way provides a small but safe ‘‘surgical margin’’.
Our sample size is small however we encountered 38, out of 80,
malignant and potentially malignant after histopathology. InTable 1 The radiological presentation of the study group (80
cases).
Radiological presentation Number Percentage
Small mass 30 37.5
Unclassiﬁed microcalciﬁcations alone 18 22.5
Unclassiﬁed microcalciﬁcations with mass 16 20
Asymmetric density 6 7.5
Focal distortion 4 5
Clustered microcysts 6 7.5
Total 80 100
Table 2 The BIRADS classiﬁcation of the study group (80
cases).
BIRADS category Number Percentage
BIRADS 3 44 55
BIRADS 4a 12 15
BIRADS 4b 18 22.5
BIRADS 4c 6 7.5
Total 80 100
Table 3 The Histopathology after BLES in comparison to open su
Pathology after BLES No. Percentage Free
Fibrocystic changes 6 7.5
Fibroadenoma 6 7.5
Sclerosing adenosis 12 15
Papilloma 14 17.5
Radial scar 4 5
ADH 14 17.5 (12/1
ALH 8 10 (7/8)
LCIS 2 2.5 (1/2)
DCIS 8 10 (6/8)
IDC 6 7.5 (3/6)
Total 80 100 (29/3about 29/38 (76.3%) the excised margin was free. This was
in accordance with the work and results published before (14).
Vacuum-assisted core needle biopsy procedures are the
established alternative to open surgery as an initial diagnostic
intervention. However, DCIS underestimation has persisted as
a limitation to the procedure. Introduction of the 11-gauge de-
vice has been reported to reduce DCIS upgrade rates, with re-
ports ranging from 20.0% to as low as 6.8% (17). In our study
we encountered DCIS in eight lesions, all were re-assessed by
open surgery and there was no underestimation by the total
en-bloc using the BLES. Our results are in agreement with
Killebrew & Oneson 2006. They compared the results of
VAB to BLES and they found underestimation by the BLES
in only 3.2% as compared to 19.4% by the VAB (11). We
are implying that these data indicate a possibility to use the
BLES as a therapeutic procedure for DCIS, reducing the error
that can be obtained by VAB and the other sampling method
thus may in the future alleviate the need to re-surgery after
BLES biopsy in DCIS and the other high risk lesions. How-
ever, an important future work may be to embark upon a pro-
spective therapeutic study of this technique in its efﬁcacy at
achieving margin status in malignant disease (13).
5. Conclusion
Indeterminate small breast lesions and unclassiﬁed microcalci-
ﬁcations can be managed successfully by using a BLES biopsy.
Lesions are in majority completely excised and thus the pathol-
ogists can be conﬁdent in their diagnosis particularly in setting
of many borderline lesions where small foci of malignancy can
be subtle. BLESS is an available option for management of
small non palpable mass when surgery is not preferred either
by the surgeon or the patient. BLES is an important addition
to the so far established procedures that can improve early
breast cancer detection.
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